Compare Kinross Gold Corporation (KGC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Kinross Gold Corporation trades at $24.25 (market cap $28.07B), while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Kinross Gold Corporation is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals.
| KGC | ZBH | |
|---|---|---|
Market Cap | $28.07B | $17.20B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $107.71 |
52-Week Low | $15.42 | $79.58 |
Enterprise Value | $26.62B | $24.25B |
Dividend Yield | 0.62% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.43, up 3.79% on the day, with strong fundamentals including a P/E of 9.59 and robust profitability metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results due July 29, 2026. Technical indicators show bearish momentum despite oversold RSI conditions, while analyst consensus remains strongly bullish with a $37.20 price target representing 59% upside potential.
KGC presents a compelling value opportunity with attractive valuation multiples and strong cash flow generation. Key risks include gold price volatility and rising operational costs. The stock's current discount to analyst targets and improving financial trajectory suggest potential for significant appreciation, though investors should monitor Q2 earnings and gold market dynamics closely.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
